idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Idiopathic%20pulmonary%20fibrosis Management

Follow Up

  • Follow-up is recommended every 3 months for patients with rapid disease progression or health status deterioration
  • Six-month intervals for follow-up is recommended for patients with steadily progressing disease
  • Follow-up every 6 months is recommended for patients with stable disease & annual follow-up for patients with stable disease after 1 year
  • Patients with ongoing pulmonary rehabilitation should be reassessed at 6- or 12-month intervals
  • Pulse oximetry measurement at rest & during exertion is recommended during follow-up (3-6 month intervals) to monitor for oxygenation status
    • Oxygen desaturation of <88% prompts supplemental oxygenation 
  • Screening for complications (pulmonary hypertension, pulmonary embolism, coronary artery disease, lung cancer) may be done every follow-up
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.